PolyPid appoints Dr. Tweezer-Zaks as chief medical officer

PETACH TIKVA, Israel - PolyPid Ltd. (NASDAQ:PYPD), a clinical-stage biopharma company with a market capitalization of $32.92 million, announced Tuesday the appointment of Dr. Nurit Tweezer-Zaks as Chief Medical Officer, effective August 18, 2025. Dr. Tweezer-Zaks will step down from her current position on the company’s Board of Directors, which she has held since November 2023.

The appointment comes following PolyPid’s positive Phase 3 SHIELD II trial results. The late-stage biopharma company is preparing for a New Drug Application submission for D-PLEX100, its lead product candidate for the prevention of abdominal colorectal surgical site infections, expected in early 2026. According to InvestingPro data, the company faces financial challenges with negative EBITDA of $27.73 million and a current ratio of 0.71, indicating potential liquidity concerns.

Dr. Tweezer-Zaks brings significant medical and executive experience to the role. She previously served as Chief Executive Officer of MediCane Health Inc. and held senior positions at aMOON Venture Capital Fund and Sanofi. Her career began as a practicing internal medicine and rheumatology physician at Sheba Medical Center in Israel, where she worked for nearly 15 years.

"I look forward to leading our medical affairs strategies as we prepare for regulatory submissions for D-PLEX and advance our pipeline, including our recently unveiled GLP-1 program," said Dr. Tweezer-Zaks in the press release.

PolyPid’s proprietary PLEX technology enables controlled, prolonged-release therapeutics for surgical outcomes. Beyond its lead candidate, the company is developing a pipeline focused on oncology, obesity, and diabetes applications.

Dr. Tweezer-Zaks holds M.D. and B.S. degrees from Ben-Gurion University School of Medicine and an M.B.A. from the Kellogg-Recanati International Executive MBA Program. With the company’s next earnings report due on August 13, 2025, InvestingPro subscribers can access 8 additional key ProTips and comprehensive financial analysis through the Pro Research Report, helping investors make informed decisions about this clinical-stage biotech company.

In other recent news, PolyPid Ltd. announced a new drug delivery platform that releases GLP-1 receptor agonists subcutaneously for approximately 60 days. This advancement extends the current standard of weekly injections for diabetes and weight management treatments. Additionally, PolyPid reported positive Phase 3 trial results for its D-PLEX100 product, significantly reducing surgical site infections by 58% in abdominal surgeries, which could lead to a New Drug Application to the FDA in early 2026. Analyst firm JMP Securities lowered its price target on PolyPid to $14 from $16, citing potential dilution from new warrants but maintained a Market Outperform rating. Meanwhile, H.C. Wainwright initiated coverage with a Buy rating and an $11 price target, emphasizing the potential of PolyPid’s PLEX technology. In corporate developments, PolyPid’s chairman, Jacob Harel, will not seek re-election at the upcoming Annual and Extraordinary General Meeting. Harel has served as a director since November 2017 and as chairman since December 2017. These recent developments reflect ongoing changes and advancements within the company.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.